Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Venture Life Group PLC (LSE:VLG): Why This AIM Stock Is in Focus on 22 October 2026 and What Comes Next

The principal identifiable area of investor interest is brand sales and commercial execution. This is a focus area, not confirmation that a fresh price-moving announcement occurred today.

Ankur Sharma | 22 October 2026

NIOX Group Plc (LSE:NIOX): Why This AIM Stock Is in Focus on 22 October 2026 and What Comes Next

NIOX Group Plc (LSE:NIOX) draws attention for point-of-care respiratory diagnostics and capital returns.

Ankur Sharma | 22 October 2026

Optima Health PLC (LSE:OPT): Why This Aim Healthcare Stock Deserves Attention on 22 October 2026

The relevant market is London’s AIM growth market. Inclusion in the AIM market does not itself establish membership of a benchmark index or a positive share-price move.

Ankur Sharma | 22 October 2026

Optima Health PLC (LSE:OPT): Why This AIM Stock Is in Focus on 22 October 2026 and What Comes Next

Optima Health PLC (LSE:OPT) draws attention for occupational health services and corporate wellbeing.

Ankur Sharma | 22 October 2026

Provexis PLC (LSE:PXS): Why This Aim Healthcare Stock Deserves Attention on 22 October 2026

The relevant market is London’s AIM growth market. Inclusion in the AIM market does not itself establish membership of a benchmark index or a positive share-price move.

Ankur Sharma | 22 October 2026

Physiomics provides mathematical modelling, data science and biostatistics services for drug development: What Could Move Physiomics plc Next? (LSE:PYC)

Physiomics plc (LSE:PYC) remains a stock for investors to assess through company-specific milestones rather than broad market sentiment alone.

Ankur Sharma | 22 October 2026

Hemogenyx Pharmaceuticals PLC (LSE:HEMO): New Feasibility Collaboration Encourages Therapy Platform Optimism

A recent feasibility agreement will evaluate targeted lipid-nanoparticle delivery of the company’s therapeutic messenger-RNA approach. The work explores a potential route towards an in-vivo cell-therapy platform. This is a specific recent scientific development that can attract renewed attention, but the agreement is exploratory. It …

Ankur Sharma | 22 October 2026

Can CelLBxHealth plc Convert Its Technology Promise Into Commercial Progress? (LSE:CLBX)

CelLBxHealth plc (LSE:CLBX) is in focus for investors assessing the UK’s smaller listed companies because its performance is closely linked to circulating tumour cell technology and cancer research tools. On 22 October 2026, the key question is not simply whether the share price moves …

Ankur Sharma | 22 October 2026

Cambridge Nutritional Sciences PLC (LSE:CNSL): Why This Aim Healthcare Stock Deserves Attention on 22 October 2026

The relevant market is London’s AIM growth market. Inclusion in the AIM market does not itself establish membership of a benchmark index or a positive share-price move.

Ankur Sharma | 22 October 2026

Eden Research PLC (LSE:EDEN): London AIM Share Spotlight as Investors Weigh Biological Crop Protection and the Next Catalyst

the investment case for Eden Research PLC (LSE:EDEN) is best assessed through the interaction of company-specific execution and wider London small-cap sentiment. The relevant business exposure is biopesticides and sustainable crop protection. Investors may revisit the stock when sector news, liquidity conditions or corporate …

Ankur Sharma | 22 October 2026
Support

Hi! How can we help you today?

Loading…